X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-04-17 | KALV | Kalvista Pharmaceuticals, Inc. | Audhya Paul K. | CHIEF MEDICAL OFFICER | S - Sale+OE | $20.22 | -2,686 | 142,547 | -2% | -$54,301 | |||||
| D | 2026-04-17 | KALV | Kalvista Pharmaceuticals, Inc. | Sweeny Nicole | Chief Commercial Officer | S - Sale+OE | $20.22 | -1,862 | 51,391 | -3% | -$37,643 | |||||
| D | 2026-04-17 | KALV | Kalvista Pharmaceuticals, Inc. | Piekos Brian | CFO | S - Sale+OE | $20.22 | -1,862 | 18,150 | -9% | -$37,643 | |||||
| D | 2026-04-17 | KALV | Kalvista Pharmaceuticals, Inc. | Palleiko Benjamin L | CEO | S - Sale+OE | $20.22 | -9,550 | 462,577 | -2% | -$193,066 | |||||
| D | 2026-04-20 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO | S - Sale+OE | $23.61 | -15,000 | 362,152 | -4% | -$354,146 | |||||
2026-04-16 | ROIV | Roivant Sciences Ltd. | Gline Matthew | CEO | S - Sale | $29.16 | -289,774 | 16,736,116 | -2% | -$8,449,810 | ||||||
| D | 2026-04-20 | KLRA | Kailera Therapeutics, Inc. | Bain Capital Investors LLC | 10% | P - Purchase | $16.00 | +8,398,438 | 26,255,581 | +47% | +$134,375,008 | |||||
| D | 2026-04-20 | KLRA | Kailera Therapeutics, Inc. | Koppel Adam | Dir, 10% | P - Purchase | $16.00 | +1,562,500 | 22,583,268 | +7% | +$25,000,000 | |||||
| D | 2026-04-20 | KLRA | Kailera Therapeutics, Inc. | Bain Capital Life Sciences Investors, LLC | 10% | P - Purchase | $16.00 | +1,562,500 | 22,583,268 | +7% | +$25,000,000 | |||||
| D | 2026-04-20 | KLRA | Kailera Therapeutics, Inc. | Kaplan Andrew T. | Dir, 10% | P - Purchase | $16.00 | +8,398,438 | 26,255,581 | +47% | +$134,375,008 | |||||
| D | 2026-04-17 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $586.66 | -9,500 | 679,797 | -1% | -$5,573,223 | |||||
2026-04-17 | BLTE | Belite Bio, Inc | Mata Nathan L. | Chief Scientific Officer | S - Sale | $161.63 | -1,000 | 13,666 | -7% | -$161,630 | ||||||
2026-04-16 | BLTE | Belite Bio, Inc | Mata Nathan L. | Chief Scientific Officer | S - Sale | $160.38 | -1,000 | 14,666 | -6% | -$160,381 | ||||||
2026-04-16 | MIST | Milestone Pharmaceuticals Inc. | Oliveto Joseph | Pres, CEO | S - Sale | $2.26 | -36,500 | 446,244 | -8% | -$82,490 | ||||||
2026-04-16 | PHVS | Pharvaris N.V. | Modig Berndt | CEO | S - Sale | $28.60 | -2,292 | 1,089,792 | 0% | -$65,559 | ||||||
| M | 2026-04-15 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $6.43 | -39,162 | 362,729 | -10% | -$251,898 | |||||
2026-04-15 | IONS | Ionis Pharmaceuticals Inc | Parshall B Lynne | Dir | S - Sale | $76.27 | -5,000 | 51,344 | -9% | -$381,367 | ||||||
| D | 2026-04-16 | IONS | Ionis Pharmaceuticals Inc | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | S - Sale+OE | $75.17 | -4,902 | 23,713 | -17% | -$368,488 | |||||
| D | 2026-04-16 | IONS | Ionis Pharmaceuticals Inc | Birchler Brian | EVP, Corp, Development Ops | S - Sale+OE | $75.04 | -973 | 67,500 | -1% | -$73,016 | |||||
| D | 2026-04-16 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $74.56 | -5,619 | 50,882 | -10% | -$418,953 | |||||
| D | 2026-04-15 | SEPN | Septerna, Inc. | Bhatt Elizabeth | Pres, COO | S - Sale+OE | $24.34 | -4,000 | 174,209 | -2% | -$97,343 | |||||
| DM | 2026-04-16 | SDGR | Schrodinger, Inc. | Farid Ramy | Pres, CEO | S - Sale+OE | $12.27 | -86,000 | 405,351 | -18% | -$1,055,177 | |||||
2026-04-16 | SDGR | Schrodinger, Inc. | Jain Rachit | EVP, CFO | S - Sale | $12.75 | -844 | 51,752 | -2% | -$10,758 | ||||||
| D | 2026-04-17 | UTHR | United Therapeutics Corp | Patusky Christopher | Dir | S - Sale+OE | $578.88 | -1,000 | 2,590 | -28% | -$578,880 | |||||
| D | 2026-04-16 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $577.21 | -9,500 | 679,797 | -1% | -$5,483,484 | |||||
| D | 2026-04-16 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $577.18 | -10,000 | 18,876 | -35% | -$5,771,765 | |||||
| D | 2026-04-15 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $23.01 | -12,500 | 196,141 | -6% | -$287,591 | |||||
2026-04-15 | PCSA | Processa Pharmaceuticals, Inc. | Young David | Pres Research, Development | P - Purchase | $2.97 | +1,545 | 14,523 | +12% | +$4,589 | ||||||
2026-04-15 | PCSA | Processa Pharmaceuticals, Inc. | Ng George K | CEO | P - Purchase | $2.97 | +1,843 | 9,780 | +23% | +$5,474 | ||||||
| M | 2026-04-15 | WHWK | Whitehawk Therapeutics, Inc. | Giacobello Scott M. | CFO | S - Sale | $4.03 | -218,600 | 295,224 | -43% | -$882,028 | |||||
2026-04-15 | PCSA | Processa Pharmaceuticals, Inc. | Lin Patrick | Chief Business - Strategy Off | P - Purchase | $2.97 | +1,369 | 6,465 | +27% | +$4,066 | ||||||
2026-04-15 | PCSA | Processa Pharmaceuticals, Inc. | Guy Wendy | Chief Administrative Officer | P - Purchase | $2.97 | +1,583 | 5,026 | +46% | +$4,702 | ||||||
2026-04-15 | PCSA | Processa Pharmaceuticals, Inc. | Bigora Sian | Chief Development Officer | P - Purchase | $2.97 | +1,799 | 5,777 | +45% | +$5,343 | ||||||
2026-04-15 | PCSA | Processa Pharmaceuticals, Inc. | Skibsted Russell | CFO | P - Purchase | $2.97 | +1,984 | 4,308 | +85% | +$5,892 | ||||||
| D | 2026-04-16 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $143.97 | -10,699 | 535,109 | -2% | -$1,540,332 | |||||
2026-04-15 | KROS | Keros Therapeutics, Inc. | Bienaime Jean Jacques | Dir | P - Purchase | $11.70 | +1,000 | 8,450 | +13% | +$11,700 | ||||||
2026-04-15 | MPLT | Maplight Therapeutics, Inc. | Kreitzer Anatol | Chief Discovery Officer | S - Sale | $26.61 | -3,316 | 256,612 | -1% | -$88,239 | ||||||
2026-04-15 | MPLT | Maplight Therapeutics, Inc. | Gillis Jonathan | CAAO, PAO | S - Sale | $26.61 | -3,590 | 251,054 | -1% | -$95,530 | ||||||
| M | 2026-04-15 | MPLT | Maplight Therapeutics, Inc. | Hanson Kristopher | GC | S - Sale | $26.89 | -1,827 | 190,165 | -1% | -$49,134 | |||||
| M | 2026-04-15 | MPLT | Maplight Therapeutics, Inc. | Setia Vishwas | CFO | S - Sale | $26.89 | -2,922 | 392,627 | -1% | -$78,572 | |||||
| M | 2026-04-15 | MPLT | Maplight Therapeutics, Inc. | Lillie James Woodruff | Chief Scientific Officer | S - Sale | $27.16 | -4,513 | 295,157 | -2% | -$122,574 | |||||
| M | 2026-04-15 | MPLT | Maplight Therapeutics, Inc. | Foff Erin Pennock | Chief Medical Officer | S - Sale | $27.03 | -3,213 | 400,777 | -1% | -$86,859 | |||||
| D | 2026-04-15 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $127.24 | -4,302 | 0 | -100% | -$547,399 | |||||
| M | 2026-04-15 | MPLT | Maplight Therapeutics, Inc. | Kroeger Christopher A. | CEO | S - Sale | $27.16 | -19,187 | 1,731,754 | -1% | -$521,146 | |||||
2026-04-15 | MPLT | Maplight Therapeutics, Inc. | Malenka Robert C. | Dir | S - Sale | $26.90 | -8,593 | 348,138 | -2% | -$231,152 | ||||||
| M | 2026-04-15 | DYN | Dyne Therapeutics, Inc. | Kersten Dirk | Dir | S - Sale | $20.35 | -99,613 | 4,544,773 | -2% | -$2,027,158 | |||||
| D | 2026-04-15 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale+OE | $6.29 | -41,668 | 1,820,978 | -2% | -$261,954 | |||||
| D | 2026-04-15 | MIRM | Mirum Pharmaceuticals, Inc. | Ramasastry Saira | Dir | S - Sale+OE | $96.90 | -2,000 | 0 | -100% | -$193,800 | |||||
| M | 2026-04-14 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $40.21 | -53,300 | 2,626,128 | -2% | -$2,143,323 | |||||
| DM | 2026-04-14 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $40.14 | -142,390 | 353,356 | -29% | -$5,715,240 | |||||
| DM | 2026-04-14 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale+OE | $56.89 | -21,120 | 133,840 | -14% | -$1,201,595 | |||||
| D | 2026-04-15 | TNGX | Tango Therapeutics, Inc. | Crystal Adam | Pres, R, D | S - Sale+OE | $25.00 | -38,460 | 112,622 | -25% | -$961,500 | |||||
| M | 2026-04-14 | SION | Sionna Therapeutics, Inc. | Thompson Peter A. | Dir | S - Sale | $44.94 | -510,583 | 3,020,119 | -14% | -$22,945,044 | |||||
| M | 2026-04-14 | SION | Sionna Therapeutics, Inc. | Orbimed Advisors LLC | Dir | S - Sale | $44.94 | -510,583 | 3,020,119 | -14% | -$22,945,044 | |||||
| DM | 2026-03-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $579.69 | -19,075 | 679,797 | -3% | -$11,057,621 | |||||
| D | 2026-04-16 | UTHR | United Therapeutics Corp | Mahon Paul A | EVP, GC | S - Sale+OE | $576.82 | -8,300 | 45,172 | -16% | -$4,787,597 | |||||
2026-04-14 | ALZN | Alzamend Neuro, Inc. | Ault Milton C III | Dir | P - Purchase | $1.00 | +108,388 | 127,777 | +559% | +$108,897 | ||||||
2026-04-15 | BLTE | Belite Bio, Inc | Mata Nathan L. | Chief Scientific Officer | S - Sale | $168.30 | -1,000 | 15,666 | -6% | -$168,298 | ||||||
2026-04-14 | MLTX | Moonlake Immunotherapeutics | Bodenstedt Matthias | CFO | S - Sale | $19.56 | -2,426 | 1,186,084 | 0% | -$47,453 | ||||||
| D | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | Lyons Gary A | Dir | S - Sale+OE | $41.07 | -8,000 | 57,500 | -12% | -$328,560 | |||||
| D | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | Baynes Roy D. | Dir | S - Sale+OE | $41.29 | -32,750 | 37,500 | -47% | -$1,352,130 | |||||
| D | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | Calvin Sandra | SVP, Chief Accounting Officer | S - Sale+OE | $41.07 | -21,977 | 42,353 | -34% | -$902,595 | |||||
| M | 2026-04-14 | ONCO | Onconetix, Inc. | Hrt Financial LP | 10% | P - Purchase | $0.76 | +166,904 | 197,052 | +554% | +$127,591 | |||||
| A | 2026-04-15 | ACIU | Ac Immune Sa | Pfeifer Andrea | CEO | S - Sale | $3.14 | -10,000 | 3,844,288 | 0% | -$31,425 | |||||
2026-04-15 | ACIU | Ac Immune Sa | Pfeifer Andrea | CEO | P - Purchase | $3.14 | +10,000 | 3,844,288 | 0% | +$31,425 | ||||||
2026-04-14 | TVTX | Travere Therapeutics, Inc. | Heerma Peter | Chief Commercial Officer | S - Sale | $41.93 | -7,215 | 138,608 | -5% | -$302,516 | ||||||
2026-04-15 | TVTX | Travere Therapeutics, Inc. | Dube Eric M | CEO | S - Sale | $41.09 | -64,000 | 432,886 | -13% | -$2,629,975 | ||||||
| DM | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | GC, GC | S - Sale+OE | $41.29 | -51,500 | 105,211 | -33% | -$2,126,452 | |||||
| M | 2026-04-13 | TVTX | Travere Therapeutics, Inc. | Cline Christopher R. | CFO | S - Sale | $41.91 | -8,327 | 116,899 | -7% | -$348,974 | |||||
| M | 2026-04-14 | TVTX | Travere Therapeutics, Inc. | Inrig Jula | Chief Medical Officer | S - Sale | $42.01 | -8,233 | 111,473 | -7% | -$345,893 | |||||
| DM | 2026-04-13 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $26.89 | -20,406 | 69,792 | -23% | -$548,672 | |||||
2026-04-13 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | CEO | S - Sale | $26.83 | -15,730 | 689,321 | -2% | -$421,979 | ||||||
| M | 2026-04-13 | WHWK | Whitehawk Therapeutics, Inc. | Ball Bryan | See remarks | S - Sale | $3.60 | -118,849 | 397,106 | -23% | -$427,860 | |||||
2026-04-14 | GNPX | Genprex, Inc. | Longnecker Brent M | Dir | S - Sale | $1.23 | -18 | 9,157 | 0% | -$22 | ||||||
| D | 2026-04-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Chief Medical Officer | S - Sale+OE | $66.12 | -7,000 | 33,377 | -17% | -$462,830 | |||||
2026-04-15 | CYTK | Cytokinetics Inc | Callos Andrew | EVP, Chief Commercial Officer | S - Sale | $66.02 | -7,449 | 58,555 | -11% | -$491,783 | ||||||
2026-04-15 | CYTK | Cytokinetics Inc | Blum Robert I | Pres, CEO | S - Sale | $65.38 | -7,500 | 419,496 | -2% | -$490,350 | ||||||
2026-04-13 | IRON | Disc Medicine, Inc. | Savage William Jacob | Chief Medical Officer | S - Sale | $66.38 | -5,731 | 79,480 | -7% | -$380,449 | ||||||
2026-04-14 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale | $44.05 | -22,951 | 457,274 | -5% | -$1,011,051 | ||||||
| M | 2026-04-13 | IRON | Disc Medicine, Inc. | Franchi Jean M. | CFO | S - Sale | $69.23 | -6,657 | 64,333 | -9% | -$460,834 | |||||
| M | 2026-04-10 | MLTX | Moonlake Immunotherapeutics | Santos Da Silva Jorge | CEO | S - Sale | $18.35 | -150,000 | 2,924,893 | -5% | -$2,752,163 | |||||
| D | 2026-04-13 | LQDA | Liquidia Corp | Moomaw Scott | Chief Commercial Officer | S - Sale+OE | $38.34 | -10,547 | 184,558 | -5% | -$404,402 | |||||
| D | 2026-04-13 | LQDA | Liquidia Corp | Adair Jason | Chief Business Officer | S - Sale+OE | $38.37 | -7,301 | 215,426 | -3% | -$280,139 | |||||
| D | 2026-04-13 | LQDA | Liquidia Corp | Boyle Dana | Chief Accounting Officer | S - Sale+OE | $38.37 | -5,101 | 176,918 | -3% | -$195,725 | |||||
| DM | 2026-04-10 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $39.36 | -42,779 | 405,775 | -10% | -$1,683,667 | |||||
| D | 2026-04-13 | LQDA | Liquidia Corp | Krepp Sarah | Chief Human Resource Officer | S - Sale+OE | $38.37 | -4,557 | 147,019 | -3% | -$174,852 | |||||
| D | 2026-04-13 | LQDA | Liquidia Corp | Saggar Rajeev | Chief Medical Officer | S - Sale+OE | $38.37 | -9,220 | 173,270 | -5% | -$353,771 | |||||
| D | 2026-04-13 | LQDA | Liquidia Corp | Schundler Russell | GC | S - Sale+OE | $38.37 | -13,692 | 625,032 | -2% | -$525,362 | |||||
| DM | 2026-04-13 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale+OE | $39.06 | -54,177 | 2,679,428 | -2% | -$2,116,264 | |||||
| D | 2026-04-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $574.86 | -9,500 | 679,872 | -1% | -$5,461,199 | |||||
| D | 2026-04-13 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $574.88 | -10,000 | 18,876 | -35% | -$5,748,802 | |||||
2026-04-10 | ANNX | Annexon, Inc. | Carson William H. | Dir | P - Purchase | $6.20 | +8,000 | 70,405 | +13% | +$49,600 | ||||||
| M | 2026-04-10 | RAPP | Rapport Therapeutics, Inc. | Yeleswaram Krishnaswamy | Chief Development Officer | S - Sale | $35.03 | -19,865 | 266,651 | -7% | -$695,823 | |||||
| D | 2026-04-09 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $27.38 | -2,170 | 76,140 | -3% | -$59,415 | |||||
| M | 2026-04-09 | WHWK | Whitehawk Therapeutics, Inc. | Ball Bryan | See remarks | S - Sale | $3.55 | -56,596 | 515,955 | -10% | -$201,124 | |||||
| D | 2026-04-09 | NTHI | Neonc Technologies Holdings, Inc. | Suh, David Jr. | Chief Accounting Officer | P - Purchase | $5.00 | +200 | 111,866 | 0% | +$1,000 | |||||
| M | 2026-04-09 | BBIO | Bridgebio Pharma, Inc. | Kumar Neil | CEO | S - Sale | $74.61 | -80,000 | 5,228,584 | -2% | -$5,968,780 | |||||
2026-04-09 | LQDA | Liquidia Corp | Jeffs Roger | CEO | S - Sale | $40.12 | -25,000 | 2,705,438 | -1% | -$1,002,888 | ||||||
| D | 2026-04-09 | LQDA | Liquidia Corp | Kaseta Michael | CFO, COO | S - Sale+OE | $40.24 | -133,789 | 411,855 | -25% | -$5,383,388 | |||||
| M | 2026-02-18 | ACET | Adicet Bio, Inc. | Ra Capital Management, L.P. | 10% | P - Purchase | $7.17 | +223,596 | 1,182,624 | +23% | +$1,603,934 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |